The Need for an Iterative Process for Assessing Economic Outcomes Associated with SSRIs
- 1 September 2000
- journal article
- review article
- Published by Springer Nature in PharmacoEconomics
- Vol. 18 (3) , 205-214
- https://doi.org/10.2165/00019053-200018030-00001
Abstract
Pharmacotherapeutic advances in the treatment of depression have included the development of the selective serotonin reuptake inhibitors (SSRIs), thereby providing alternatives to tricyclic...Keywords
This publication has 144 references indexed in Scilit:
- Antidepressant Selection and Use and Healthcare ExpendituresPharmacoEconomics, 1998
- Constraints on Antidepressant Prescribing and Principles of Cost-Effective Antidepressant UsePharmacoEconomics, 1997
- Changing Patterns of Antidepressant Use and Costs in a Health Maintenance OrganisationPharmacoEconomics, 1997
- Making cost assessments based on RCTs more useful to decision-makersHealth Policy, 1996
- The Added Costs of Depression to Medical CarePharmacoEconomics, 1995
- A critical review of health-related economic evaluations in Australia: implications for health policyHealth Policy, 1995
- Comparative Tolerability Profiles of the Newer versus Older AntidepressantsDrug Safety, 1994
- The Role of Insurance Claims Databases in Drug Therapy Outcomes ResearchPharmacoEconomics, 1993
- Guidelines for Economic Analysis of Pharmaceutical ProductsPharmacoEconomics, 1993
- Cost-utility in practice: A policy maker's guide to the state of the artHealth Policy, 1992